Chinese biotech firm claims ‘Longevity Pill’ could extend human life to 150 years

A Shenzhen-based company announces a breakthrough anti-ageing pill that targets “zombie cells,” but global scientists urge caution as evidence remains limited to early animal trials.

A major claim from China has sparked global curiosity and debate after a Shenzhen-based biotechnology company announced that it has developed a longevity pill capable of significantly slowing ageing. According to the company, the pill could potentially help humans live up to 150 years by targeting ageing mechanisms at the cellular level.

The pill has been designed to focus on senescent cells, commonly referred to as “zombie cells.” These cells no longer divide, yet they continue to release chemicals that trigger inflammation and accelerate ageing-related diseases. Scientists worldwide have been studying ways to neutralise or remove these cells, which are considered one of the key contributors to ageing.

Also Read:Karnataka brings spas and salons under KPME Act to curb unqualified cosmetic procedures

Early experiments on mice have shown promising results. Reports indicate a 9.4% increase in their overall lifespan. After receiving the treatment, their remaining life expectancy increased by more than 64%, an outcome that has drawn significant attention from researchers and investors.

Longevity research was once a niche interest in China, often considered a fascination limited to wealthy Americans. But the trend has shifted, with several Chinese citizens and companies now investing heavily in anti-ageing science and biotechnology.

Also Read:Kupendra Reddy urges government-opposition unity to secure Bengaluru’s future

Despite the excitement, global scientific communities are urging caution. Experts stress that findings from mouse trials represent only an initial step and cannot be directly applied to humans. Long-term, large-scale human clinical trials will be essential to establish the pill’s safety, effectiveness, and real-world impact on human ageing.